Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1

NCT02840058 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

295

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

OTHER: Biological samples
DRUG: Anti PD1/PDL1 treatment

Sponsor

Centre Hospitalier Universitaire de Besancon